ARMISTICE CAPITAL, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001601086
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2025 · 359 positions · Total reported value $7.99B · Top-10 concentration 63.6% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 80.3% · 158 new · 82 cut · 148 exited
Active Share (vs S&P 500): 94.8% · vs QQQ: 95.6% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -2.0% · vs SPY -4.1% · Prev Value $7.59B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): +0.3% · vs SPY -1.9% · Latest Value $7.32B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q4 2025 13F filing, ARMISTICE CAPITAL, LLC disclosed 359 equity positions with a combined reported value of $7.99B. The filing implies a focused portfolio: its ten largest positions account for 63.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / High Turnover.
The largest disclosed positions as of Q4 2025 were SPY ($2.05B), IWM ($1.99B), PTCT ($212.83M). By sector, the heaviest allocations are Health Care 30.7%, Consumer Discretionary 7.4%. Versus the prior quarter, allocation shifted toward Consumer Discretionary (+1.5pp) and away from Technology (-1.0pp), Health Care (-1.2pp).
Versus the prior quarter, ARMISTICE CAPITAL, LLC opened 158 new positions, trimmed 82 and fully exited 148, a turnover rate of 80.3% of positions. The portfolio's overlap with the prior quarter was 35% of names.
The largest new positions opened in Q4 2025 were KVUE ($68.87M), GSK ($49.04M), DXCM ($21.44M).
Of the 148 positions fully exited versus the prior quarter, the largest were EXAS ($56.38M), VRTX ($15.76M), CHDN ($9.06M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2025)
Fully Exited (vs previous quarter)
- EXAS EXACT SCIENCES CORP · prev qtr: $56.38M
- VRTX VERTEX PHARMACEUTICALS INC · prev qtr: $15.76M
- CHDN CHURCHILL DOWNS INC · prev qtr: $9.06M
- VNRX VOLITIONRX LTD · prev qtr: $6.37M
- SXT SENSIENT TECHNOLOGIES CORP · prev qtr: $6.35M
- PLNT PLANET FITNESS MASTER ISSUER · prev qtr: $5.81M
- CCL CARNIVAL CORP LTD · prev qtr: $4.54M
- META META PLATFORMS INC · prev qtr: $4.06M
Insider Transactions (Form 4)
Latest ARMISTICE CAPITAL, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Armistice Capital is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 325 US equity positions with a combined value of $7.59B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-100464 (status: Approved), registered 2015-07-02
- Regulatory AUM (Form ADV): $4.72B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
- Website: armisticecapital.com
Portfolio Structure
- 325 positions · $7.59B reported value (Q2 2026)
- Top 10 holdings = 65.2% of reported value
- Largest position: SPY (STATE STR SPDR S&P 500 ETF T) at 31.5%
- Average position size: $23.35M
Sector Tilt
- Health Care 29.3%
- Information Technology 7.4%
- Consumer Discretionary 5.2%
- (classified holdings cover 45% of value)
Quarterly Activity
- Q2 2026: 168 new, 72 added, 65 reduced, 96 exited
- 20 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
3.00M | $2.05B | 25.60% | Add | |
| 2 |
|
8.10M | $1.99B | 24.95% | Add | |
| 3 |
|
2.80M | $212.83M | 2.66% | Reduce | |
| 4 |
|
265.70K | $154.73M | 1.94% | Add | |
| 5 |
|
3.76M | $143.82M | 1.80% | Reduce | |
| 6 |
|
2.76M | $137.37M | 1.72% | Reduce | |
| 7 |
|
820.24K | $116.33M | 1.46% | Add | |
| 8 |
|
1.10M | $108.46M | 1.36% | Reduce | |
| 9 |
|
367.63K | $84.86M | 1.06% | Add | |
| 10 |
|
7.30M | $83.42M | 1.04% | Add | |
| 11 |
|
3.00M | $81.66M | 1.02% | Add | |
| 12 |
|
1.30M | $78.97M | 0.99% | Add | |
| 13 |
|
3.99M | $68.87M | 0.86% | New | |
| 14 |
|
792.00K | $64.96M | 0.81% | Hold | |
| 15 |
|
84.00K | $64.84M | 0.81% | Reduce | |
| 16 |
|
3.25M | $63.56M | 0.80% | Add | |
| 17 |
|
992.77K | $63.08M | 0.79% | Reduce | |
| 18 |
|
196.42K | $61.48M | 0.77% | Reduce | |
| 19 |
|
118.34K | $57.23M | 0.72% | Add | |
| 20 |
|
16.02M | $54.00M | 0.68% | Reduce | |
| 21 |
|
4.94M | $51.29M | 0.64% | Add | |
| 22 |
|
657.98K | $50.03M | 0.63% | Add | |
| 23 |
|
1.00M | $49.04M | 0.61% | New | |
| 24 |
|
58.00K | $48.78M | 0.61% | Hold | |
| 25 |
|
319.10K | $46.77M | 0.58% | Add | |
| 26 |
|
549.80K | $46.30M | 0.58% | Add | |
| 27 |
|
3.10M | $45.67M | 0.57% | Add | |
| 28 |
|
2.65M | $40.14M | 0.50% | Add | |
| 29 |
|
499.39K | $39.66M | 0.50% | Add | |
| 30 |
|
1.10M | $38.11M | 0.48% | Add | |
| 31 |
|
62.84K | $36.41M | 0.46% | Add | |
| 32 |
|
2.42M | $36.33M | 0.46% | Reduce | |
| 33 |
|
1.80M | $36.09M | 0.45% | Reduce | |
| 34 |
|
3.20M | $35.94M | 0.45% | Add | |
| 35 |
|
836.00K | $35.81M | 0.45% | Add | |
| 36 |
|
17.50M | $34.83M | 0.44% | Add | |
| 37 |
|
61.07K | $34.59M | 0.43% | Add | |
| 38 |
|
244.54K | $33.25M | 0.42% | Add | |
| 39 |
|
653.80K | $33.11M | 0.41% | Add | |
| 40 |
|
676.00K | $32.76M | 0.41% | Add | |
| 41 |
|
858.92K | $32.24M | 0.40% | Add | |
| 42 |
|
936.00K | $30.64M | 0.38% | Reduce | |
| 43 |
|
1.54M | $27.34M | 0.34% | Reduce | |
| 44 |
|
3.54M | $27.30M | 0.34% | Add | |
| 45 |
|
68.00K | $27.29M | 0.34% | Add | |
| 46 |
|
271.24K | $26.06M | 0.33% | Add | |
| 47 |
|
2.77M | $25.88M | 0.32% | Add | |
| 48 |
|
596.00K | $25.20M | 0.32% | Add | |
| 49 |
|
394.71K | $25.15M | 0.32% | Add | |
| 50 |
|
1.52M | $24.99M | 0.31% | Add | |
FAQ
What did ARMISTICE CAPITAL, LLC buy in 2025-Q4?
In its 2025-Q4 13F filing, ARMISTICE CAPITAL, LLC reported 359 equity positions worth $7.99B in aggregate; its largest disclosed positions were SPY ($2.05B), IWM ($1.99B), PTCT ($212.83M).
How large is ARMISTICE CAPITAL, LLC's portfolio?
ARMISTICE CAPITAL, LLC reported $7.99B of long equity holdings across 359 positions as of 2025-Q4. Top-10 holdings account for 63.6% of reported value.
What is ARMISTICE CAPITAL, LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.